Status:
WITHDRAWN
Irbesartan Versus Amlodipine: The OBI Study
Lead Sponsor:
Aristotle University Of Thessaloniki
Conditions:
Obesity
Hypertension
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
Objective: 1. To study the effectiveness of irbesartan 300mg and amlodipine 10 mg in 24h ambulatory blood pressure values in obese subjects 2. To study the drug specific effect in arterial stiffness ...
Detailed Description
Study Objectives 1. Primary: * Reduction of 24h BP in obese hypertensives * Reduction in arterial stiffness 2. Secondary * Drug specific effect on new onset of diabetes * Drug specific ...
Eligibility Criteria
Inclusion
- Age between 18 and 60 years.
- All patients are going to give their informed consent to participate in the study.
- Stage I hypertension.
- BMI \> 30.
Exclusion
- Known oversensitiveness,
- Chronic renal disease (GFR \< 50 ml/min) or ESRD,
- Heart or respiratory failure, OR
- Recent MI, shock, liver deficiency (ALT or AST \> 3 times normal and pregnancy or lactation.
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00987662
Start Date
January 1 2012
End Date
January 1 2014
Last Update
February 11 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hypertension-24h ABPM Center Papageorgiou Hospital
Thessaloniki, Greece